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Summary
Rotavirus is the most common cause o f  severe gastroenteritis in infants and young children worldwide. Before initiation o f  the 
rotavirus vaccination program in the United States in 2006, approximately 80% o f  U.S. children had rotavirus gastroenteri­
tis by age 5  years. Each year during the 1990s and early 2000s, rotavirus resulted in approximately 410,000 physician visits,
205,000-272,000 emergency department visits, and 55,000-70,000 hospitalizations among U.S. infants and children, with 
total annual direct and indirect costs o f  approximately $1 billion. In February 2006, a live, oral, human-bovine reassortant 
rotavirus vaccine (RotaTeq® [RV5]) was licensed as a 3-dose series for use among U.S. infants for the prevention o f  rotavirus 
gastroenteritis, and the Advisory Committee on Immunization Practices (ACIP) recommended routine use o f RV5 among U.S. 
infants (CDC. Prevention o f  rotavirus gastroenteritis among infants and children: recommendations o f the Advisory Committee 
on Immunization Practices [ACIP]. M M W R  2006;55[No. RR-12]). In April 2008, a live, oral, human attenuated rotavirus 
vaccine (Rotarix® [RV1]) was licensed as a 2-dose series for use among U.S. infants, and in June 2008, ACIP updated its rotavi­
rus vaccine recommendations to include use o f  RV1. This report updates and replaces the 2006ACIP statement for prevention o f 
rotavirus gastroenteritis. ACIP recommends routine vaccination o f U.S. infants with rotavirus vaccine. RV5 and RV1 differ in 
composition and schedule o f  administration. RV5 is to be administered orally in a 3-dose series, with doses administered at ages 
2, 4, and 6  months. RV1 is to be administered orally in a 2-dose series, with doses administered at ages 2 and 4  months. ACIP  
does not express a preference for either RV5 or RV1. The recommendations in this report also address the maximum ages for doses, 
contraindications, precautions, and special situations for the administration o f rotavirus vaccine.
Introduction
Rotavirus is the most common cause of severe gastroenteritis 
in infants and young children worldwide. Rotavirus causes 
approximately half a million deaths each year among children 
aged <5 years, with >80% of deaths occurring in developing 
countries (1). In the United States during the prevaccine era, 
rotavirus gastroenteritis resulted in relatively few childhood 
deaths (approximately 20-60 deaths per year among children 
aged <5 years) (2—5). However, before initiation o f the rota­
virus vaccination program in 2006, nearly every child in the 
United States was infected with rotavirus by age 5 years; the 
majority had gastroenteritis, resulting annually during the 
1990s and early 2000s in approximately 410,000 physician
The material in this report originated in the N ational C enter for 
Immunization and Respiratory Diseases, Anne Schuchat, M D , Director, 
and the Division o f Viral Diseases, Larry Anderson, M D , Director. 
Corresponding preparer: M argaret M. Cortese, M D , National Center 
for Im munization and Respiratory Diseases, C D C , 1600 Clifton Rd., 
N E, MS A-47, A tlanta GA 30333. Telephone: 404-639-1929; Fax: 
404-639-8665; E-mail: mcortese@cdc.gov.
visits, 205,000-272,000 emergency department (ED) visits,
55,000-70,000 hospitalizations, and total annual direct and 
indirect costs of approximately $1 billion (5—9) (Figure 1). 
This report presents the recommendations of the Advisory 
Committee on Immunization Practices (ACIP) for use of two
FIGURE 1. Estimated number of annual deaths, hospita liza­
tions, emergency department v is its , and episodes of rotavirus 
gastroenteritis among children aged <5 years before in troduc­
tion of rotavirus vaccine — United States
2 MMWR February 6, 2009
rotavirus vaccines among U.S. infants: RotaTeq® (RV5) (Merck 
and Company, Whitehouse Station, New Jersey), which was 
licensed by the Food and Drug Administration (FDA) in 
February 2006 (10) and Rotarix® (RV1) (GlaxoSmithKline 
[GSK] Biologicals, Rixensart, Belgium), which was licensed 
by FDA in April 2008 (11). This report updates and replaces 
the 2006 ACIP statement for prevention of rotavirus gastro­
enteritis (12).
B ackgro un d
Clinical and Epidemiologic Features 
of Rotavirus Disease in the 
Prevaccine Era
In the prevaccine era, rotavirus infected almost all children by 
age 5 years; severe dehydrating gastroenteritis caused by rota­
virus occurred primarily among children aged 4-23  months 
(13—15). Rotavirus infects the proximal small intestine, where 
it elaborates an enterotoxin and destroys the epithelial surface, 
resulting in blunted villi, extensive damage, and shedding of 
massive quantities o f virus in stool (13). The estimated incu­
bation period for rotavirus diarrheal illness is <48 hours (16). 
Under experimental conditions, adults who became ill had 
symptoms 1—4 days after receiving rotavirus orally (17,18). 
The clinical spectrum of rotavirus illness in children ranges 
from mild, watery diarrhea of limited duration to severe diar­
rhea with vomiting and fever than can result in dehydration 
with shock, electrolyte imbalance, and death (19). The illness 
usually begins with acute onset of fever and vomiting, followed 
24-48 hours later by frequent, watery stools (20,21). Up to 
one third of children with rotavirus illness have a temperature 
of >102°F (>39°C) (22,23). Vomiting usually lasts <24 hours; 
other gastrointestinal symptoms generally resolve in 3 -7  days. 
Rotavirus protein and ribonucleic acid (RNA) have been 
detected in blood, organs, and cerebrospinal fluid, but the 
clinical implications o f these findings are not clear (20,24).
Rotaviruses are shed in high concentrations (i.e., 1012 virus 
particles per gram of stool during the acute illness) in the stools 
of infected children before and several days after clinical disease 
(25). Rotavirus is transmitted primarily by the fecal-oral route, 
both through close person-to-person contact and through 
fomites (26). Very few infectious virions are needed to cause 
disease in susceptible hosts (25). Spread is common within 
families. O f adult contacts of infected children, 30% -50%  
become infected, although infections in adults often are 
asymptomatic because of immunity from previous exposure 
(27—29). Transmission o f rotavirus through contaminated 
water or food is likely to be rare (30,31). Transmission through
airborne droplets also has been hypothesized but remains 
unproven (21,30,32).
In the United States, rotavirus causes w inter seasonal 
peaks o f gastroenteritis, with activity beginning usually in 
the southwestern states during December-January, moving 
across the country, and ending in the northeastern states in 
April-May (33—35). Rotavirus might account for up to 10% 
of gastroenteritis episodes among children aged <5 years (36). 
Infants and children with rotavirus gastroenteritis are likely 
to have more severe symptoms than those with nonrotavirus 
gastroenteritis (22,23,37,38). In the prevaccine era, rotavirus 
accounted for 30% -50%  of all hospitalizations for gastroen­
teritis among U.S. children aged <5 years and up to 70% of 
hospitalizations for gastroenteritis during the seasonal peak 
months (7,14,39—44). O f all the rotavirus hospitalizations that 
occurred among children aged <5 years in the United States 
during the prevaccine era, 17% occurred during the first 6 
months of life, 40% by age 1 year, and 75% by age 2 years 
(Figure 2). Rotavirus accounted for 20% -40%  of outpatient 
clinic visits during the rotavirus season (14,45,46). Before the 
initiation of the rotavirus vaccination program, four of five 
children in the United States had rotavirus gastroenteritis by 
age 5 years (36,39,47), one in seven required a clinic or ED 
visit, one in 70 were hospitalized, and one in 200,000 died 
from this disease (3,8). Active, population-based surveillance 
from early 2006 and before vaccine was used provided annual 
rotavirus hospitalization and ED visit rates of 22.4 and 301
FIGURE 2. Cumulative proportion of children hospitalized with 
an In ternationa l C lassification o f Diseases, N in th  Revision- 
Clin ica l M odifications code fo r rotavirus gastroenteritis among 
children aged <5 years, by age group — United States, National 
Hospital D ischarge Survey, 1993-2002*
Age (months)
‘Calculated from the database used in Charles MD, Holman RC, Curns AT, Parashar UD, Glass RI, Bresee JS. Hospitalizations associated with rotavirus gastroenteritis in the United States, 1993-2002. Pediatr Infect Dis J 2006;25:489-93.
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per 10,000 children aged <3 years, respectively (14). Rotavirus 
also was an important cause of hospital-acquired gastroenteritis 
among children (48).
In a recent study, factors associated with increased risk for 
hospitalization for rotavirus gastroenteritis among U.S. chil­
dren included lack of breastfeeding, low birth weight (a likely 
proxy for prematurity), daycare attendance, the presence of 
another child aged <24 months in the household, and either 
having Medicaid insurance or having no medical insurance 
(49). Another study identified low birth weight, maternal fac­
tors (e.g., young age, having Medicaid insurance, and maternal 
smoking), and male gender as risk factors for hospitalization 
with viral gastroenteritis (50). These studies suggest that 
preterm infants are at higher risk for severe rotavirus disease. 
Children and adults who are immunocompromised because 
of congenital immunodeficiency or because o f bone marrow 
or solid organ transplantation sometimes experience severe 
or prolonged rotavirus gastroenteritis (51—56). The severity 
o f rotavirus disease among children infected with hum an 
immunodeficiency virus (HIV) might be similar to that among 
children without HIV  infection (57). W hether the incidence 
rate of severe rotavirus disease among HIV-infected children 
is similar to or greater than that among children without HIV 
infection is not known.
Laboratory Testing for Rotavirus
Because the clinical features o f rotavirus gastroenteritis 
do not differ distinctly from those of gastroenteritis caused 
by other pathogens, confirmation o f rotavirus infection by 
laboratory testing of fecal specimens is necessary for reliable 
rotavirus surveillance and can be useful (e.g., for infection- 
control purposes) in clinical settings. The most widely used 
diagnostic laboratory method is antigen detection in the stool 
by an enzyme immunoassay (EIA) directed at an antigen 
common to all group A rotaviruses (i.e., those that are the 
principal cause of human disease). Certain commercial EIA 
kits are available that are easy to use, rapid, and highly sensitive, 
making them suitable for rotavirus surveillance and clinical 
diagnosis. O ther techniques, including electron microscopy, 
RNA electrophoresis, reverse transcription-polymerase chain 
reaction (RT-PCR), sequence analysis, and culture are used 
primarily in research settings.
Serologic methods that detect a rise in serum antibodies, pri­
marily EIA for rotavirus serum immunoglobulin G (IgG) and 
immunoglobulin A (IgA) antibodies, have been used to confirm 
recent infections primarily in the research setting. In vaccine tri­
als, the immunogenicity of rotavirus vaccines has been assessed 
by measuring rotavirus-specific IgG, IgA and neutralizing anti­
bodies to the serotypes of the vaccine strains (58—60).
Morphology, Antigen Composition, 
and Immune Response
Rotaviruses are 70-nm nonenveloped RNA viruses in the 
family Reoviridae (61,62). The viral nucleocapsid is composed 
of three concentric shells that enclose 11 segments of double­
stranded RNA. The outermost layer contains two structural 
viral proteins (VP): VP4, the protease-cleaved protein (P pro­
tein) and VP7, the glycoprotein (G protein). These two proteins 
define the serotype of the virus and are considered critical to 
vaccine development because they are targets for neutralizing 
antibodies that are believed to be important for protection 
(61,62). Because the two gene segments that encode these 
proteins can segregate independently, a typing system consist­
ing of both P and G types has been developed (63). Although 
characterizing G serotypes by traditional methods is straight­
forward, using these methods for determining P serotypes is 
more difficult. Consequently, molecular methods are used 
almost exclusively to define genetically distinct P genotypes 
by nucleotide sequencing. These genotypes correlate well with 
known serotypes, but they are designated in brackets (e.g., P[8]) 
to distinguish them from P serotypes determined by antigenic 
analyses. In the United States, viruses containing six distinct 
P and G combinations are most prevalent: P[8]G1, P[4]G2, 
P[8]G3, P[8]G4, P[8]G9, P[6]G9 (64—67) (Figure 3).
Several animal species (e.g., primates and cows) are suscep­
tible to rotavirus infection and suffer from rotavirus diarrhea, 
but animal strains of rotavirus differ from those that infect 
humans. Although human rotavirus strains that possess a high 
degree of genetic homology with animal strains have been 
identified (63,68—71), animal-to-human transmission appears
FIGURE 3. Prevalent s tra ins of ro tavirus — United States, 
1996-2005
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to be uncommon. However, natural reassortant animal-human 
strains have been identified in humans (63), and some are being 
developed as vaccine candidates (72).
Although children can be infected with rotavirus several 
times during their lives, initial infection after age 3 months 
is most likely to cause severe gastroenteritis and dehydration 
(15,73—75). After a single natural infection, 38% of children 
are protected against subsequent infection with rotavirus, 77% 
are protected against subsequent rotavirus gastroenteritis, and 
87% are protected against severe rotavirus gastroenteritis; sec­
ond and third infections confer progressively greater protection 
against rotavirus gastroenteritis (75). Rotavirus infection in 
healthy full-term neonates often is asymptomatic or results in 
only mild disease, perhaps because of protection from passively 
transferred maternal antibody (13,76).
The immune correlates of protection from rotavirus infec­
tion and disease are not understood fully. Both serum and 
mucosal antibodies probably are associated with protection, 
and in some studies, serum antibodies against VP7 and VP4 
have correlated with protection (58,59). However, in other 
studies, including vaccine studies, correlation between serum 
antibody and protection has been poor (77). First infections 
with rotavirus generally elicit a predominantly homotypic, 
serum-neutralizing antibody response, and subsequent infec­
tions typically elicit a broader, heterotypic response (21,78). 
The influence o f cell-mediated immunity is understood less 
clearly but probably is related both to recovery from infection 
and to protection against subsequent disease (79,80).
Rotavirus Vaccines  
Background
In 1998, ACIP recommended Rotashield® (RRV-TV) (Wyeth 
Lederle Vaccines and Pediatrics, Marietta, Pennsylvania) (81), 
a rhesus-based tetravalent rotavirus vaccine, for routine vac­
cination of U.S. infants, with 3 doses administered at ages 
2, 4, and 6 months (82). However, RRV-TV was withdrawn 
from the U.S. market within 1 year of its introduction because 
of its association with intussusception (83). At the time of 
its withdrawal, RRV-TV had not yet been introduced in any 
other national vaccination program globally. The risk for 
intussusception was most elevated (>20-fold increase) within 
3-14  days after receipt of dose 1 of RRV-TV, with a smaller 
(approximately fivefold) increase in risk within 3 -14  days 
after receipt of dose 2 (84). Overall, the estimated risk associ­
ated with dose 1 o f RRV-TV was approximately one case per 
10,000 vaccine recipients (85). After they reassessed the data 
on RRV-TV and intussusception, certain researchers suggested
that the risk for intussusception was age-dependent and that 
the absolute number of intussusception events, and possibly 
the relative risk for intussusception associated with dose 1 of 
RRV-TV increased with increasing age at vaccination (86,87). 
However, after reviewing all the available data, the World 
Health Organization (W HO) Global Advisory Committee 
on Vaccine Safety (GACVS) concluded that the risk for RRV- 
TV-associated intussusception was high in infants vaccinated 
after age 60 days and that insufficient evidence was available to 
conclude that the use o f RRV-TV at age <60 days was associ­
ated with a lower risk (88). GACVS noted that the possibility 
of an age-dependent risk for intussusception should be taken 
into account in assessing rotavirus vaccines.
M ethodology
The ACIP rotavirus vaccine workgroup was reestablished in 
July 2007, after submission of the Biologics License Application 
(BLA) for RV1 to FDA in June 2007. The workgroup held 
teleconferences at least m onthly to review published and 
unpublished data on the burden and epidemiology of rotavirus 
disease in the United States, the safety and efficacy o f RV1 and 
RV5, and cost-effectiveness analyses. Recommendation options 
were developed and discussed by ACIP’s rotavirus vaccine work 
group. The opinions of workgroup members and other experts 
were considered when data were lacking. Programmatic aspects 
related to implementation of the recommendations were taken 
into account. Presentations were made to ACIP during meet­
ings in October 2007 and February 2008. The final proposed 
recommendations were presented to ACIP at the June 2008 
ACIP meeting; after discussion, minor modifications were 
made, and the recommendations were approved.
Pentavalent H um an-Bovine  
Reassortant Rotavirus Vaccine  
(Rotateq® [RV5])
RV5, which was licensed in the United States in 2006, is 
a live, oral vaccine that contains five reassortant rotaviruses 
developed from human and bovine parent rotavirus strains 
(Box) (10,89). Four reassortant rotaviruses express one of the 
outer capsid proteins (G1, G2, G3, or G4) from the human 
rotavirus parent strains and the attachment protein (P7[5]) 
from the bovine rotavirus parent strain. The fifth reassortant 
virus expresses the attachment protein (P1A[8]) from the 
human rotavirus parent strain and the outer capsid protein 
(G6) from the bovine rotavirus parent strain. The parent bovine 
rotavirus strain, Wistar Calf 3 (WC3), was isolated in 1981 
from a calf with diarrhea in Chester County, Pennsylvania,
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BOX. Characteristics of RotaTeq® (RV5) and Rotarix® (RV1)
Characteristic RV5 RV1
Parent rotavirus strain Bovine strain W C3 (type G6P7[5]) Hum an strain 89-12 (type G1P1A[8])
Vaccine composition Reassortant strains
G l x W C3; G2 x W C3; G3 x W C3;
G4 x W C3; P1A[8] x W C3
Hum an strain 89-12 (type G1P1A[8])
Vaccine titer >2.0-2.8 x 106 infectious units (IU) per 
dose, depending on serotype
>106.° median cell culture infective dose 
(CCID50) after reconstitution, per dose
Cell culture substrate Vero cells Vero cells
Formulation Liquid requiring no reconstitution Vial of lyophilized vaccine with a prefilled 
oral applicator o f liquid diluent (1 ml)
Applicator Latex-free dosing tube Tip cap and rubber plunger of the oral 
applicator contain dry natural latex rubber. 
The vial stopper and transfer adapter are 
latex-free.
O ther content Sucrose, sodium citrate, sodium phosphate 
monobasic monohydrate, sodium hydroxide, 
polysorbate 80, cell culture media, and trace 
amounts of fetal bovine serum.
Lyophilized vaccine: amino acids, dextran, 
Dulbecco’s Modified Eagle Medium, sorbitol, 
and sucrose.
Liquid diluent contains calcium carbonate, 
sterile water, and xanthan
Preservatives None None
Shelf life 24 months 24 months
Storage Store refrigerated at 36°F—46°F (2°C—8°C). 
Administer as soon as possible after being 
removed from refrigeration. Protect from 
light.
Storage before reconstitution: Refrigerate 
vials o f lyophilized vaccine at 36°F-46°F 
(2°C-8°C); diluent may be stored at a 
controlled room temperature of 68°F-77°F 
(20°C-25°C). Protect vials from light.
Storage after reconstitution: Administer 
within 24 hours of reconstitution. May be 
stored refrigerated at 36°F-46°F (2°C-8°C) 
or at room temperature up to 77°F (25°C), 
after reconstitution.
Volume per dose 2 ml 1 ml
and was passaged 12 times in African green monkey kidney The RV5 BLA contained three phase III trials (91). Data
cells (90). The reassortants are propagated in Vero cells using from these trials on the immunogenicity, efficacy, and safety
standard tissue culture techniques in the absence of antifungal of RV5 are summarized below.
agents. The licensed vaccine is a ready-to-use 2 ml solution that
contains >2.0-2.8 x 106 infectious units (IUs) per individual
reassortant dose, depending on serotype.
P l e a s e  n o t e :  A n  e r r a t u m  h a s  b e e n  p u b l i s h e d  f o r  t h i s  i s s u e .  T o  v i e w  t h e  e r r a t u m ,  p l e a s e  c l i c k  h e r e .
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Immunogenicity
A relation between antibody responses to rotavirus vaccina­
tion and protection against rotavirus gastroenteritis has not 
been established. In clinical trials, a rise in titer of rotavirus 
group-specific serum IgA antibodies was used as one of the 
measures o f the immunogenicity of RV5. Sera were collected 
before vaccination and at 2—6 weeks after dose 3, and serocon­
version was defined as a threefold or greater rise in antibody 
titer from baseline. Seroconversion rates for IgA antibody to 
rotavirus were 93% -100%  among 439 RV5 recipients com­
pared with 12% -20%  in 397 placebo recipients in phase III 
studies (91).
Antibody responses to concomitantly administered vaccines 
were evaluated in a study with a total of 662 RV5 recipients 
and 696 placebo recipients. Different subsets of infants were 
evaluated for specific antibody responses. A 3-dose series of 
RV5 did not diminish the immune response to concomitantly 
administered Haemophilus influenzae type b conjugate (Hib) 
vaccine, inactivated poliovirus vaccine (IPV), hepatitis B 
(HepB) vaccine, pneumococcal conjugate vaccine (PCV), and 
diphtheria and tetanus toxoids and acellular pertussis (DTaP) 
vaccine (10,91).
Efficacy
The efficacy of the final formulation of RV5 has been evalu­
ated in two phase III trials among healthy infants (92,93). 
Administration of oral polio vaccine (OPV) was not allowed; 
concomitant administration of other vaccines was not restricted. 
The large Rotavirus Efficacy and Safety Trial (REST) included 
a clinical efficacy substudy (Tables 1 and 2). In this substudy, 
4,512 infants from Finland and the United States were included 
in the primary per-protocol efficacy analysis (consisting of 
evaluable subjects for whom there was no protocol violation) 
through one rotavirus season. The primary efficacy endpoint 
was the prevention of wild type G 1-G 4 rotavirus gastroen­
teritis occurring >14 days after completion o f a 3-dose series 
through the first full rotavirus season after vaccination. A case 
of rotavirus gastroenteritis was defined as production of three 
or more watery or looser-than-normal stools within a 24-hour 
period or forceful vomiting, along with rotavirus detection 
by EIA in a stool specimen obtained within 14 days after the 
onset of symptoms. G serotypes were identified by RT-PCR 
followed by sequencing. Severe gastroenteritis was defined as a 
score of >16 on an established 24-point severity scoring system 
(Clark score) on the basis of intensity and duration o f fever, 
vomiting, diarrhea, and changes in behavior.
The efficacy o f RV5 against G 1-G 4 rotavirus gastroen­
teritis of any grade of severity through the first full rotavirus 
season after vaccination was 74.0% (95% confidence interval
[CI] = 66.8-79.9) and against severe G 1-G 4 rotavirus gastro­
enteritis was 98.0% (CI = 88.3-100.0) (Table 2). RV5 reduced 
office or clinic visits for G 1-G 4 rotavirus gastroenteritis by 
86.0% (CI = 73.9-92.5). In a trial that evaluated RV5 at the 
end of its shelf life, the efficacy estimates for RV5 based on 
per-protocol analysis of data from 551 RV5 recipients and 564 
placebo recipients were similar to those identified in the clini­
cal efficacy substudy (10,92,93). Among the limited number 
of infants from phase III trials who received at least 1 dose of 
RV5 (n = 144) or placebo (n = 135) >10 weeks after a previous 
dose, the estimate of efficacy of the RV5 series for protection 
against G 1-G 4 rotavirus gastroenteritis of any severity was 
63% (CI = 53% -94% ) (94).
In the health-care utilization cohort of REST, data from 
57,134 infants from 11 countries were included in the per- 
protocol analysis of the efficacy of RV5 in reducing the need 
for hospitalization or ED care for rotavirus gastroenteritis (93). 
The efficacy o f the RV5 series against ED visits for G 1-G 4 
rotavirus gastroenteritis was 93.7% (CI = 88.8-96.5), and effi­
cacy against hospitalization for G 1-G 4 rotavirus gastroenteritis 
was 95.8% (CI = 90.5-98.2) (Table 2). Efficacy was observed 
against all G 1-G 4 and G9 serotypes (Table 3); relatively few 
non-G1 rotavirus cases were detected. The efficacy of RV5 
against all gastroenteritis-related hospitalizations was 58.9% 
(CI = 51.7-65.0) for the period that started after dose 1.
Breastfeeding did not appear to diminish the efficacy of a 
3-dose series of RV5. Post-hoc analyses o f the clinical efficacy 
substudy found that the efficacy of RV5 against G 1-G 4 rota­
virus gastroenteritis of any severity through the first rotavirus 
season was similar among the 1,632 infants (815 in the vac­
cine group and 817 in the placebo group) who never were 
breastfed (68.3%; CI = 46.1-82.1) and the 1,566 infants 
(767 in the vaccine group and 799 in the placebo group) who 
were exclusively breastfed (68.0%; CI = 53.8-78.3) (95). 
Efficacy against severe G 1-G 4 rotavirus gastroenteritis also 
was similar among infants who never were breastfed (100.0%; 
CI = 48.3-100.0) and those who were exclusively breastfed 
(100.0%; CI = 79.3-100.0).
In posthoc analyses of data from the clinical efficacy substudy 
of REST, efficacy also was estimated among 73 healthy preterm 
infants (gestational age of <37 weeks) who received RV5 and 
78 healthy preterm infants who received placebo (96). The 
efficacy through the first full season against rotavirus gastro­
enteritis o f any severity (all serotypes combined) was 73.0% 
(CI = -2.2-95.2); three cases occurred among RV5 recipients, 
and 11 cases occurred among placebo recipients. In the health­
care utilization cohort, the efficacy against rotavirus gastroen­
teritis-attributable hospitalizations (all serotypes combined) for 
healthy preterm infants was 100.0% (CI = 53.0-100.0); no 
cases were identified among 764 preterm infants who received
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TABLE 1. Characteristics o f the major efficacy tria ls of Rotarix® (RV1) and RotaTeq® (RV5)
Characteristic RV1 Latin America* RV1 Europe^ RV5 REST§1
Study locations (Vaccine:placebo 
enrollment ratio)
Latin America (1:1) Europe (2:1) Primarily United States and Finland (1:1)
Vaccine Placebo Total Vaccine Placebo Total Vaccine Placebo Total
No. of infants included in efficacy analyses 
Year 1 ATP** 9,009 8,858 17,867 2,572 1,302 3,874 2,207 2,305 4,512
Year 2 ATP 7,175 7,062 14,237 2,554 1,294 3,848 813 756 1,569
Health-care use cohort — — — — — — 28,646 28,488 57,134
Age at doses, per protocol
Primary efficacy endpoint
Dose 1: 6-12 wks 6 days (for one 
country, 6-13 wks 6 days)
Dose 2: 1-2 mos later, at age <24 
wks 6 days
Prevention of severe rotavirus 
gastroenteritis caused by circulating 
wild-type strains from 2 wks after 
dose 2 until age 1 year
Dose 1: 6-14 wks 6 days
Dose 2: 1-2 mos later, at age <24 wks 6 days
Dose 1: 6-12 wks 0 days 
Subsequent doses: 4-10 wks apart 
Dose 3: age <32 wks 0 days
Prevention of rotavirus gastroenteritis of Prevention of wild-type G1-G4 rotavirus
any severity caused by circulating wild- gastroenteritis >14 days after dose 3
type strains from 2 wks after dose 2 until through first full rotavirus season after
end of first rotavirus season vaccination
* SOURCES: Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22. 
Food and Drug Administration. Rotarix clinical review. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2008. Available at http://www. 
fda.gov/cber/products/rotarix/rotarix031008rev.pdf. 
t  SOURCE: Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: 
randomised, double-blind controlled study. Lancet 2007;370:1757-63.
§ Rotavirus Efficacy and Safety Trial. Efficacy was evaluated among two cohorts: clinical efficacy cohort (the United States and Finland) and health-care utilization cohort (11 countries, 
with 80% of infants from the United States and Finland).
H SOURCES: Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33. 
Food and Drug Administration. Product approval information-licensing action, package insert: RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalant), Merck. Rockville, MD: US 
Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2006.
** According to protocol.
RV5 and nine cases were identified among 818 preterm infants 
who received placebo. Efficacy against rotavirus gastroenteritis- 
attributable ED visits was 100% (CI = 66.6-100.0), with no 
cases identified among RV5 recipients and 12 cases identified 
among placebo recipients (96).
Adverse Events After Vaccination
Intussusception
REST was designed as a large trial to permit evaluation 
o f safety with respect to intussusception; 69,625 enrolled 
infants received at least 1 dose of RV5 or placebo (10,93). No 
increased risk for intussusception was observed in this trial 
after administration of RV5 when compared with placebo. For 
the prespecified period of days 0-42 after any dose, six con­
firmed intussusception cases occurred among 34,837 infants 
who received RV5, and five confirmed intussusception cases 
occurred among 34,788 infants who received placebo (relative 
risk adjusted for group sequential design: 1.6; CI = 0.4-6.4). 
None o f the infants with confirmed intussusception in either 
treatment group had onset during days 1-21 after dose 1.
other Adverse Events
Serious adverse events (SAEs) and deaths were evaluated in 
infants enrolled in phase III trials (10,97). Among RV5 and 
placebo recipients, the incidence of SAEs within 42 days of 
any dose (2.4% of 36,150 and 2.6% of 35,536, respectively)
was similar. Across the studies, the incidence of death was 
similar among RV5 recipients (<0.1% [n = 25]) and placebo 
recipients (<0.1% [n = 27]). The most common cause o f death 
(accounting for 17 ([32.7%]) of 52 deaths) was sudden infant 
death syndrome (SIDS), which was observed in eight RV5 
recipients and nine placebo recipients.
Gastroenteritis occurring anytime after a dose was reported 
as an SAE in 76 (0.2%) RV5 recipients and in 129 (0.4%) 
placebo recipients. Seizures reported as SAEs occurred in 
27 (<0.1%) vaccine recipients and in 18 (<0.1%) placebo 
recipients (difference not statistically significant). Pneumonia 
occurring anytime after a dose was reported as an SAE in 59 
(0.2%) o f RV5 recipients and in 62 (0.2%) of placebo recipi­
ents; hospitalization for pneumonia within 7 days after any 
dose occurred in 11 (<0.1%) RV5 recipients and in 14 (<0.1%) 
placebo recipients (91).
A subset o f 11,711 infants was studied in detail to assess 
other potential adverse experiences (10). In the 42-day period 
postvaccination of any dose of RV5, the incidence o f fever 
reported by parents and guardians of RV5 recipients and pla­
cebo recipients (42.6% and 42.8%, respectively) was similar, 
as was the incidence of hematochezia reported as an adverse 
experience (0.6% in both RV5 recipients and placebo recipi­
ents). Some (e.g., diarrhea, vomiting) adverse events occurred 
at a statistically higher incidence within 42 days of any dose 
in RV5 recipients (Table 4). Statistical significance was deter­
mined using 95% CIs on the risk difference; intervals with a
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TABLE 2. Efficacy of Rotarix® (RV1) and RotaTeq® (RV5) against rotavirus gastroenteritis (GE) in major efficacy tria ls, by severity 
and season*
No. of cases*
Rotavirus disease severity____________________________________________ Vaccine_______ Placebo_____________ % efficacy________ (95% Cl§)_____
Rotavirus GE of any severity 
RV1 Europe^
Through 1st season 24 (2,572) 94 (1,302) 87.1 (79.6-92.1)
2nd season 61 (2,554) 110 (1,294) 71.9 (61.2-79.8)
Through 2nd season** 85 (2,572) 204 (1,302) 78.9 (72.7-83.8)
RV5 RESTtt§§
Through 1st full season (types G1-G4) 82 (2,207) 315 (2,305) 74.0 (66.8-79.9)
2nd full season (types G1-G4) 36 (813) 88 (756) 62.6 (44.3-75.4)
Severe rotavirus GE 
RV1 Latin America^
To age 1 year: clinical*** 12 (9,009) 77 (8,858) 84.7 (71.7-92.4)
To age 1 year: Vesikari >11 +++ 11 (9,009) 71 (8,858) 84.8 (71.1-92.7)
2nd year: Vesikari >11 19 (7,175) 101 (7,062) 81.5 (69.6-89.3)
To age 2 years: Vesikari >11§§§ 28 (7,205) 154 (7,081) 82.1 (73.1-88.5)
RV1 Europe
Through 1st season: Vesikari >11 5 (2,572) 60 (1,302) 95.8 (89.6-98.7)
2nd season: Vesikari >11 19 (2,554) 67 (1,294) 85.6 (75.8-91.9)
Through 2nd season: Vesikari >11 24 (2,572) 127 (1,302) 90.4 (85.1-94.1)
RV5 REST
Through 1st full season: Clark>16 (types G1-G4)™ 1 (2,207) 51 (2,305) 98.0 (88.3-100)
2nd full season: Clark>16 (types G1-G4) 2 (813) 17 (756) 88.0 (49.4-98.7)
Hospitalization for rotavirus GE 
RV1 Latin America
To age 1 year 9 (9,009) 59 (8,858) 85.0 (69.6-93.5)
2nd year 15 (7,175) 80 (7,062) 81.5 (67.7-90.1)
To age 2 years 22 (7,205) 127 (7,081) 83.0 (73.1-89.7)
RV1 Europe
Through 1st season 0 (2,572) 12 (1,302) 100.0 (81.8-100)
2nd season 2 (2,554) 13 (1,294) 92.2 (65.6-99.1)
Through 2nd season 2 (2,572) 25 (1,302) 96.0 (83.8-99.5)
RV5 REST
Health-care use cohort (types G1-G4)**** 6 (28,646) 144 (28,488) 95.8 (90.5-98.2)
* Because trials were conducted in different countries and have other differences (including different case definitions and durations of follow-up), efficacy results 
between trials cannot be directly compared. Efficacy assessment periods began 2 weeks after the last dose of the series in the per-protocol analyses. The number
of persons with rotavirus cases and the number of infants who contributed to the analyses are presented; vaccine efficacy results are based on analyses using 
the follow-up time contributed by each subject. Selected results are presented.
t  Numbers in parentheses represent the number of persons who received either vaccine or placebo and were included in the per-protocol analysis.
§ Confidence interval.
H SOURCE: Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European 
infants: randomised, double-blind controlled study. Lancet 2007;370:1757-63.
** Efficacy results for “through second season" based on 2,572 RV1 recipients and 1,302 placebo recipients who entered the first efficacy period (from 2 weeks after
dose 2 up to the end of the first rotavirus season) and on 2,554 RV1 recipients and 1,294 placebo who entered the second efficacy period (from the visit at the 
end of the first rotavirus season up to the visit at the end of the second rotavirus season).
t t  Rotavirus Efficacy and Safety Trial.
§§ SOURCES: Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 
2006;354:23-33. Vesikari T, Karoven A, Ferrante SA et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq, against hospitalizations and emergency de­
partment visits up to 3 years postvaccination: the Finnish Extension Study. Presented at the 13th International Congress on Infectious Diseases, Kuala Lumpur, 
Malaysia; June 19-22, 2008. Food and Drug Administration. Product approval information-licensing action, package insert: RotaTeq (Rotavirus Vaccine, Live, Oral, 
Pentavalant), Merck. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 
2006.
HH SOURCES: Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl 
J Med 2006;354:11-22. Food and Drug Administration. Rotarix clinical review. Rockville, MD: US Department of Health and Human Services, Food and Drug 
Administration; 2008. Available at http://www.fda.gov/cber/products/rotarix/rotarix031008rev.pdf.
*** Defined as diarrhea (three or more loose or watery stools within 24 hours), with or without vomiting, that required overnight hospitalization or rehydration therapy
equivalent to World Health Organization plan B (oral rehydration) or plan C (intravenous rehydration) in a medical facility.
t t t  Defined as >11 on this 20-point clinical scoring system, based on the intensity and duration of symptoms of fever, vomiting, diarrhea, degree of dehydration, and 
treatment needed.
§§§ Efficacy results for “to age 2 years" are based on 7,205 RV1 recipients and 7,081 placebo recipients who entered the first efficacy period (from 2 weeks after dose 
2 up to age 1 year) and on 7,175 RV1 recipients and 7,062 placebo recipients who entered the second efficacy period (from age 1 year up to age 2 years).
™  Defined as >16 on this 24-point clinical scoring system, based on the intensity and duration of symptoms of fever, vomiting, diarrhea, and behavioral changes.
**** Efficacy results are based on G1-G4 rotavirus-related hospitalizations among 28,646 RV5 recipients and 28,488 placebo recipients in the health-care utilization 
cohort analysis contributing approximately 35,000 person-years of total follow-up during the first year and on a subset of the cohort (2,502 infants total) contribut­
ing approximately 1,000 person-years of follow-up during the second year.
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TABLE 3. Efficacy of Rotarix® (RV1) and RotaTeq® (RV5) against G type-specific rotavirus gastroenteritis in major efficacy tria ls, 
by severity and season*
Rotavirus type
No. of cases* 




Through 1st full season 72 (2,207) 286 (2,305) 74.9 (67.3-80.9)
Severe 
RV1 Latin America^
To age 1 yr: clinical§§ 3 (9,009) 36 (8,858) 91.8 (74.1-98.4)
To age 1 yr: Vesikari >11H1 3 (9,009) 32 (8,858) 90.8 (70.5- 98.2)
To age 2 yrs: clinical*** 10 (7,205) 55 (7,081) 82.1 (64.6-91.9)
RV1 Europet t t
Through 1st season: Vesikari >11 2 (2,572) 28 (1,302) 96.4 (85.7-99.6)
Through 2nd season: Vesikari >11 §§§ 4 (2,572) 57 (1,302) 96.4 (90.4- 99.1)
RV5 REST
Hospitalization/ED^ visits**** 16 (28,646) 328 (28,488) 95.1 (91.6-97.1)
G2
Any severity  
RV5 REST
Through 1st full season 6 (2,207) 17 (2,305) 63.4 (2.6-88.2)
Severe 
RV1 Latin America
To age 1 yr: clinical 6 (9,009) 10 (8,858) 41.0 (<0-82.4)
To age 1 yr: Vesikari >11 5 (9,009) 9 (8,858) 45.4 (<0-85.6)
To age 2 yrs: clinical 5 (7,205) 8 (7,081) 38.6 (<0-84.2)
RV1 Europe
Through 1st season: Vesikari >11 1 (2,572) 2 (1,302) 74.7 (<0-99.6)
Through 2nd season: Vesikari >11 2 (2,572) 7 (1,302) 85.5 (24.0-98.5)
RV5 REST
Hospitalization/ED visits 1 (28,646) 8 (28,488) 87.6 (<0-98.5)
G3
Any severity  
RV5 REST
Through 1st full season 1 (2,207) 6 (2,305) 82.7 (<0-99.6)
Severe 
RV1 Latin America
To age 1 yr: clinical 1 (9,009) 8 (8,858) 87.7 (8.3-99.7)
To age 2 yrs: clinical 3 (7,205) 14 (7,081) 78.9 (24.5-96.1)
RV1 Europe
Through 1st season: Vesikari >11 0 (2,572) 5 (1,302) 100.0 (44.8-100.0)
Through 2nd season: Vesikari >11 1 (2,572) 8 (1,302) 93.7 (52.8-99.9)
RV5 REST
Hospitalization/ED visits 1 (28,646) 15 (28,488) 93.4 (49.4-99.1)
G4
Any severity  
RV5 REST
Through 1st full season 3 (2,207) 6 (2,305) 48.1 (<0-91.6)
Severe 
RV1 Latin America
To age 1 yr: clinical 1 (9,009) 2 (8,858) N A tttt
To age 2 yrs: clinical 7 (7,205) 18 (7,081) 61.8 (4.1-86.5)
RV1 Europe
Through 1st season: Vesikari >11 0 (2,572) 7 (1,302) 100.0 (64.9-100.0)
Through 2nd season: Vesikari >11 1 (2,572) 11 (1,302) 95.4 (68.3-99.9)
RV5 REST




Through 1st full season 1 (2,207) 3 (2,305) 65.4 (<0-99.3)
Severe 
RV1 Latin America
To age 1 yr: clinical 2 (9,009) 21 (8,858) 90.6 (61.7-98.9)
To age 2 yrs: clinical 9 (7,205) 66 (7,081) 86.6 (73.0- 94.1)
RV1 Europe
Through 1st season: Vesikari >11 2 (2,572) 19 (1,302) 94.7 (77.9-99.4)
Through 2nd season: Vesikari >11 13 (2,572) 44 (1,302) 85.0 (71.7- 92.6)
RV5 REST
Hospitalization/ED visits 0 (28,646) 14 (28,488) 100.0 (69.6-100.0)
See Table 3 footnotes on next page.
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TABLE 3. (Continued) Efficacy of Rotarix® (RV1) and RotaTeq® (RV5) against G type-specific rotavirus gastroenteritis in major 
efficacy tria ls , by severity and season*
* Because trials were conducted in different countries and have other differences (including different case definitions and durations of follow-up), efficacy results between trials cannot be directly compared. Efficacy assessment periods began 2 weeks after the last dose of the series in the per-protocol analyses. The number of persons with rotavirus cases and the number of infants who contributed to the analyses are presented; vaccine efficacy results are based on analyses using the follow-up time contributed by each subject. Selected results are presented.t Numbers in parentheses represent the number of persons who received either vaccine or placebo and were included in the per-protocol analysis.§ Confidence interval.H Rotavirus Efficacy and Safety Trial.
** SOURCES: Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33. Food and Drug Administration. Product approval information-licensing action, package insert: RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalant), Merck. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evalua­tion and Research; 2006. Vesikari T, Karoven A, Ferrante SA et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq, against hospitalizations and emergency department visits up to 3 years postvaccination: the Finnish Extension Study. Presented at the 13th International Congress on Infectious Diseases, Kuala Lumpur, Malaysia; June 19-22, 2008.tt SOURCES: Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22. Food and Drug Administration. Rotarix clinical review. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2008. Available at http://www.fda.gov/cber/products/rotarix/rotarix031008rev.pdf.§§ Defined as diarrhea (three or more loose or watery stools within 24 hours), with or without vomiting, that required overnight hospitalization or rehydration therapy equivalent to World Health Organization plan B (oral rehydration) or plan C (intravenous rehydration) in a medical facility.Defined as >11 on this 20-point clinical scoring system, based on the intensity and duration of symptoms of fever, vomiting, diarrhea, degree of dehydra­tion, and treatment needed.*** Efficacy results for “to age 2 years" are based on 7205 RV1 recipients and 7,081 placebo recipients who entered the first efficacy period (from 2 weeks after dose 2 up to age 1 year) and on 7,175 RV1 recipients and 7,062 placebo recipients who entered the second efficacy period (from age 1 year up to age 2 years). ttt SOURCE: Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007;370:1757-63.§§§ Efficacy results for “through second season" based on 2,572 RV1 recipients and 1,302 placebo recipients who entered the first efficacy period (from 2 weeks after dose 2 up to the end of the first rotavirus season) and 2,554 RV1 recipients and 1,294 placebo who entered the second efficacy period (from the visit at the end of the first rotavirus season up to the visit at the end of the second rotavirus season).HHH Emergency department.**** Hospitalization/ED results based on 28,646 RV5 recipients and 28,488 placebo recipients in the healthcare utilization cohort analysis contributing ~35,000 person-years of total follow-up during the first year, and a subset of the cohort (2,502 infants total) contributing ~1,000 person-years of follow-up during the second year. tttt Not available.
lower bound above zero were considered statistically significant. 
Adverse events also were solicited from parents and guardians 
within the first week after each dose. RV5 recipients had a 
small but statistically significantly greater (p-value <0.05) rate 
of diarrhea and vomiting after specific doses or after any dose 
(Table 5). Among the limited number of infants from phase III 
trials who received at least 1 dose of RV5 or placebo >10 weeks 
after a previous dose (depending on dose number and specific 
adverse event monitored, the number of infants evaluated in 
either the RV5 or placebo group ranged from 211-1,182), the 
proportion of infants with adverse events appeared generally 
similar among the RV5 and placebo recipients (94).
In the phase III clinical trials, infants were followed for up to 
42 days of vaccine dose. Kawasaki disease was reported in five of 
36,160 RV5 recipients and in one o f35,536 placebo recipients 
(unadjusted relative risk: 4.9; CI = 0.6-239.1) (10).
Preterm Infants
In posthoc analyses of data from REST, adverse events were 
examined among healthy preterm infants with gestational age 
of 25-36 weeks (median: 34 weeks) (10,96). At least one SAE 
was reported within 42 days after any dose in 55 (5.5%) of 
the 1,005 preterm infants who received RV5 and in 62 (5.8%) 
of the 1,061 preterm infants who received placebo. Among 
the preterm infants with gestational age of <32 weeks, at least
one SAE was reported within 42 days of any dose in 6 (8.1%) 
of the 74 RV5 recipients and in 9 (9.8%) of the 92 placebo 
recipients. No confirmed intussusception occurred in a preterm 
infant during the study. Two deaths occurred in the RV5 group 
(one from SIDS and one from a motor-vehicle crash), and 
two occurred in the placebo group (one from SIDS and one 
from an unknown cause). The incidence o f solicited adverse 
events (fever, vomiting, diarrhea, and irritability) within 7 
days after each dose administration was assessed in preterm 
infants; depending on dose number and specific adverse event 
monitored, the number of infants evaluable in either the RV5 
or placebo group varied (range: 108-154). The rates appeared 
generally similar between the RV5 and placebo recipients.
Shedding and Transmission 
of Vaccine Virus
Fecal shedding o f rotavirus vaccine virus was evaluated by 
plaque assays with electrophenotyping in a subset of infants 
enrolled in the large phase III trial by obtaining a single stool 
sample during days 4 -6  after each dose o f RV5 (93). Vaccine 
virus was detected in 17 (12.7%) o f 134 infants after dose 1, 
zero o f 109 infants after dose 2, and zero of 99 infants after 
dose 3. Shedding of vaccine virus also was assessed for phase 
III studies overall, including that detected by plaque assays
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TABLE 4. Number and percentage of infants with adverse events 
that occurred at a statistically higher incidence among recipients 
of RotaTeq® (RV5) compared with placebo, by event*
RV5+ Placebo§
Event No. (%) No. (%)
Diarrhea 1,479 (24.1) 1,186 (21.3)Vomiting 929 (15.2) 758 (13.6)Otitis media 887 (14.5) 724 (13.0)
Nasopharyngitis 422 (6.9) 325 (5.8)Bronchospasm 66 (1.1) 40 (0.7)
SOURCE: Food and Drug Administration. Product approval information- licensing action, package insert: RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalant), Merck. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2006.* Events that occurred at a statistically higher incidence within 42 days of any dose. Statistical significance was determined using 95% confidence intervals on the risk difference; intervals with a lower bound above zero were considered statistically significant. Coadministration of routine infant vaccines was allowed in studies that provided these data. Parents and guardians were asked to report adverse events on a vaccination report card. t N = 6,138.§ N = 5,573.
of rotavirus-antigen positive stools from infants evaluated for 
possible gastroenteritis. Shedding was observed as early as 1 day 
and as late as 15 days after a dose (10). The potential for trans­
mission of vaccine virus to other persons was not assessed.
Postlicensure Rotavirus Surveillance 
Data from the United States
Rotavirus surveillance data from two systems, the National 
Respiratory and Enteric Virus Surveillance System (NREVSS) 
and the New Vaccine Surveillance Network (NVSN), indicated 
that the 2007-08 season was substantially delayed in onset and 
diminished in magnitude compared to the seasons before sub­
stantial uptake of RV5 among U.S. infants (98). NREVSS is a 
voluntary network of U.S laboratories that provides C D C  with
weekly reports o f the number of tests performed and positive 
results obtained for a variety of pathogens. For rotavirus, results 
o f EIAs are reported. Compared with the 15 previous seasons 
spanning 1991-2006, rotavirus activity during the 2007-08 
season appeared delayed in onset by 2 -4  months (Figure 4). 
Further, data from the 32 laboratories that consistently 
reported results during July 2000—May 2008 indicated that 
the number of tests positive for rotavirus during the 2007—08 
season (January 1, 2008—May 3, 2008) was lower by more than 
two thirds compared with the median number positive during 
the same weeks in the seven preceding rotavirus seasons.
Since 2006, NVSN has conducted prospective, population- 
based surveillance for rotavirus gastroenteritis among children 
aged <3 years residing in three U.S counties. Among children 
with gastroenteritis enrolled during January—April of each year, 
the overall percentage of fecal specimens testing positive for 
rotavirus was 51% in 2006, 54% in 2007, and 6% in 2008.
Although nationally representative data on vaccine cover­
age are not yet available, information from population-based 
immunization information system sentinel sites indicates that 
mean coverage with 1 dose of rotavirus vaccine among infants 
aged 3 months was 49.1% in May 2007 and 56.0% in March 
2008. Additional surveillance and epidemiologic studies are 
underway to monitor the impact of rotavirus vaccination in 
the United States.
Postlicensure Safety Monitoring Data 
from the United States
During February 2006-M arch 2008, approximately 14 
million doses of RV5 were distributed in the United States 
(99). Results from two safety monitoring systems have been 
reported. The U.S. Vaccine Adverse Event Reporting System 
(VAERS), a national passive surveillance system managed
TABLE 5. Solicited adverse events within the firs t week after doses 1, 2, and 3 of RotaTeq® (RV5) and placebo, by event and dose*


















Vomiting 6.7%t 5.4% 5.0% 4.4% 3.6% 3.2% 11.6%+ 9.9%
Diarrhea 10.4%+ 9.1% 8.6%t 6.4% 6.1% 5.4% 18.1%+ 15.3%
Irritability 7.1% 7.1% 6.0% 6.5% 4.3% 4.5% 12.9% 13.0%
Elevated temperature^ 17.1%(n = 5, 616) 16.2%(n = 5,077) 20.0%(n = 5,215) 19.4%(n = 4,725) 18.2%(n = 4,865) 17.6%(n = 4,382) 35.3%(n = 5,751) 34.1%(n = 5,209)
SOURCES: Food and Drug Administration. Product approval information-licensing action, package insert: RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalant), Merck. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2006. Merck (unpublished data, 2006).* Coadministration of routine infant vaccines was allowed in studies that provided these data. Parents and guardians were asked to monitor for these adverse events and record information on a vaccination report card. t Statistically significantly higher compared to rate in placebo recipients (p<0.05).§ Temperature >100.5°F (>38.1°C) rectal equivalent obtained by adding 1°F (0.55°C) to otic and oral temperatures and 2°F (1.1°C) to axillary temperatures.
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FIGURE 4. Percentage of rotavirus tests w ith positive results 
from  partic ipating laboratories, by week of year — National 
Respiratory and Enteric V irus Surveillance System, United 
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jointly by FDA and CDC, receives reports of adverse events 
after vaccination from multiple sources, including health-care 
providers, vaccine recipients and parents and guardians o f vac­
cine recipients, and manufacturers (100,101). Reported cases 
of intussusception among vaccine recipients are classified as 
confirmed if Brighton Collaboration Level 1 criteria are met 
(102). In VAERS analyses, the number of confirmed intus­
susception cases reported after vaccination is compared with 
the number of cases expected to occur by chance alone. This 
latter number is determined from estimates of the background 
rates of intussusception among infants and estimates of the 
total number of doses of RV5 that have been administered to 
infants. As of March 31, 2008, the number o f confirmed cases 
of intussusception reported to VAERS during either the 1—21 
day period or the 1—7  day period after receipt of any dose (doses
1, 2 , and 3 combined) of RV5 did not exceed the number 
of cases expected to occur by chance alone after vaccination 
(99,103). A relative increase in intussusception reports in the 
first week after receipt o f dose 1 of RV5, compared with the 
second and third weeks after dose 1 , has been noted; whether 
this phenomenon is related to better reporting for intussus­
ception during the first week after vaccination or represents a 
small increased risk for intussusception during the first week 
after dose 1 of RV5 is not clear (99,103).
Because VAERS is not designed to provide a definitive assess­
ment of risk, the safety of RV5 also is monitored in the Vaccine 
Safety Datalink (VSD), a collaborative project between CDC 
and several large U.S. health maintenance organizations that 
links computerized patient-level vaccination data to medical 
outcomes, including potential adverse events (104). VSD is 
able to test hypotheses suggested by VAERS reports and pre­
licensure trials. W ith >2 0 0 ,0 0 0  doses of RV5 administered 
to infants in the VSD system during May 21, 2006—May 24,
2008, the number of cases of intussusception identified that 
occurred within a 30-day period after receipt of any dose of 
RV5 was not greater than the number of cases expected to 
occur by chance alone (105). No case of intussusception was 
identified that occurred within the first week after receipt of 
the first dose of RV5 in VSD (out of approximately 77 ,000  
first doses) nor in the prelicensure REST. The data suggest 
that, if any associated risk exists, the risk for intussusception 
associated with the first dose of RV5 within the first week 
after vaccination is not greater than one in 25,000—50,000 
first doses (105).
Other adverse events monitored in VAERS, VSD, or both 
include hematochezia, Kawasaki syndrome, seizures, meningi­
tis and encephalitis, myocarditis and gram-negative sepsis. The 
data do not indicate that RV5 is associated with an increased 
risk for these adverse events (99,105).
M onovalent H um an Rotavirus  
Vaccine (Rotarix® [RV1])
RV1 is a live, oral vaccine licensed in 2008 for use in the 
United States that contains a human rotavirus strain (type 
G1P1A[8]) (Box). It was developed from a strain o f rotavirus 
(termed 89-12) that was isolated in 1988 from a child in 
Cincinnati, Ohio, and that was first attenuated by passag­
ing 33 times in African green monkey kidney cells (106); it 
was then cloned and further passaged in a Vero cell line and 
renamed RIX 4414 (107). The licensed vaccine is prepared as a 
lyophilized powder that is reconstituted with 1 ml o f a calcium 
bicarbonate buffer to a titer of >10 6̂  C C ID 50 per dose (11). 
The BLA contained six phase II trials and five phase III trials 
(108). Data from these trials on the immunogenicity, efficacy, 
and safety o f RV1 are summarized below.
Immunogenicity
A relation between antibody responses to rotavirus vac­
cination and protection against rotavirus gastroenteritis has 
not been established. In two clinical trials, seroconversion 
was defined as the appearance of antirotavirus IgA antibodies 
(concentration of >20 U/ml) postvaccination in the serum of 
infants previously negative for rotavirus IgA antibodies. In the 
two studies, 1 -2  months after a 2 -dose series, 681 (8 6 .5%) of 
787 RV1 recipients seroconverted compared with 28 (6.7%) 
o f420 placebo recipients, and 302 (76.8%) o f393 RV1 recipi­
ents seroconverted compared with 33 (9.7%) of 341 placebo 
recipients, respectively (11).
One U.S. study was designed specifically to evaluate the 
antibody responses to vaccines (DTaP-HepB-IPV, PCV7 and 
Hib) coadministered with RV1. A total of 180 infants received
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the 2 doses of RV1 coadministered with the other vaccines, 
and 137 infants who received the 2 RV1 doses 1 m onth 
after the other vaccines were included in the ATP cohort. 
Noninferiority criteria were met for all antigens, indicating 
that coadministration o f RV1 with routine childhood vaccines 
did not diminish the immune responses to any of these vaccine 
antigens (11,108).
Efficacy
The efficacy of the licensed formulation of RV1 has been 
evaluated in two large phase III trials among healthy infants, 
one conducted in 11 Latin American countries (109) and one 
conducted in six European countries (110) (Table 1). OPV was 
not coadministered; other routine childhood vaccines could 
be administered concomitantly. In both studies, both breast 
and formula feeding were permitted.
In the Latin American trial, 17,867 infants enrolled into 
the safety study also were part of the efficacy analysis and were 
included in the per-protocol efficacy analysis (Table 1) (109). 
The primary efficacy endpoint in this study was prevention of 
severe wild-type rotavirus gastroenteritis from 2 weeks after 
second dose until age 1 year. Wild-type rotavirus gastroen­
teritis was defined as an episode o f gastroenteritis in which 
rotavirus other than vaccine strain was identified in a stool 
sample collected no later than 7 days after symptom onset. A 
clinical definition for severe rotavirus gastroenteritis was used: 
diarrhea (three or more loose or watery stools within 24 hours), 
with or without vomiting, in which rotavirus other than vac­
cine strain was identified in a stool sample and that required 
overnight hospitalization or rehydration equivalent to W H O  
plan B (oral rehydration) or plan C (intravenous rehydration) 
in a medical facility. Stools were tested for the presence of 
rotavirus antigen by enzyme-linked immunosorbent assay 
(ELISA). Stools that tested positive by ELISA were analyzed 
further for G and P type determination by RT-PCR, followed 
by reverse hybridization assay or optional sequencing (108). 
For certain outcomes, severe rotavirus gastroenteritis also was 
defined as a score of >11 on an established 20-point severity 
scoring system (Vesikari scale) on the basis of the intensity and 
duration of symptoms of fever, vomiting, diarrhea, degree of 
dehydration, and treatment needed (109).
In the Latin American trial, the efficacy of RV1 against 
severe rotavirus gastroenteritis (clinical definition) after 
completion o f a 2-dose series until age 1 year was 84.7% 
(CI = 71.7-92.4) (109) (Table 2); the efficacy results were 
similar when severe rotavirus gastroenteritis was defined as an 
episode of rotavirus gastroenteritis with a Vesikari score of >11 
(84.8%; CI = 71.1-92.7). The efficacy against severe rotavirus 
gastroenteritis (clinical definition) after completion of a 2-dose
series until age 2 years was 80.5% (CI = 71.3-87.1). Efficacy 
against non-G1 strains was observed; few cases from certain 
strains were detected (Table 3). The efficacy against G2 was 
greater than zero for subjects followed to age 1 year and those 
followed to age 2 years, but the 95% CIs included zero.
The efficacy against rotavirus gastroenteritis of any severity 
was not measured in the Latin American trial. For the first 
year follow-up period, the efficacy for 2 doses o f RV1 against 
severe gastroenteritis (clinical definition) from any cause was 
40.0% (CI = 27.7-50.4) (109).
In the European trial, efficacy was assessed among 3,874 
infants who received either RV1 or placebo (110). The primary 
efficacy endpoint in this study was prevention of wild-type 
rotavirus gastroenteritis of any grade o f severity occurring 
from 2 weeks after dose 2 until the end of the first rotavirus 
season. In general, efficacy results were somewhat higher in the 
European trial than in the Latin American trial (Tables 2 and 
3). The efficacy against rotavirus gastroenteritis o f any sever­
ity after the 2-dose regimen until the end of the first rotavirus 
season was 87.1% (CI = 79.6-92.1), and efficacy against severe 
rotavirus gastroenteritis (score of >11 on the Vesikari scale) was 
95.8% (CI = 89.6-98.7) (Table 2). The efficacy after 2 doses 
of RV1 through the end of the second rotavirus season was 
78.9% (CI = 72.7-83.8) against rotavirus gastroenteritis of any 
severity, and 90.4% (CI = 85.1-94.1) against severe rotavirus 
gastroenteritis (score of >11 on the Vesikari scale). Efficacy 
against non-G1 strains was observed; few cases from certain 
strains were detected (Table 3). For the second season and 
for the combined first and second season, the efficacy against 
severe disease from G2 was positive with a 95% CI that did not 
include zero. For the first season follow-up period, the efficacy 
for 2 doses of RV1 against hospitalization for gastroenteritis 
of any cause was 74.7% (CI = 45.5-88.9).
The efficacy of RV1 against rotavirus gastroenteritis of any 
severity through the first season among infants in the European 
trial that breastfed at the time of at least 1 dose (86.0%; 
CI = 76.8-91.9) was similar to the efficacy among infants not 
breastfed at the time of either dose (90.8%; CI = 72.5-97.7) 
(108). Efficacy against severe rotavirus gastroenteritis through 
the first season also was similar for the two groups (breastfed 
at the time of at least 1 dose: 95.7% [CI = 88.2-98.9] com­
pared with not breastfed at the time of either dose: 96.2% 
[CI = 74.1-99.9]). Data on the efficacy of RV1 among preterm 
infants are not available.
Adverse Events After Vaccination
Intussusception
The Latin American trial was designed as a large trial to 
permit evaluation of safety with respect to intussusception;
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63,225 infants (including 2,060 infants from Finland) received 
at least 1 dose o f RV1 or placebo (109). No increased risk for 
intussusception was observed after administration o f RV1 
when compared with placebo. For the prespecified period 
days 0-30  after either dose, on the basis of the date of diag­
nosis, six confirmed intussuception cases occurred among 
31,673 infants who received RV1 and seven occurred among 
31,552 infants who received placebo (relative risk [RR]: 0.85; 
CI = 0.30-2.42). O n the basis o f the date of intussusception 
onset, seven confirmed intussusception cases occurred among 
RV1 recipients and seven occurred among placebo recipients 
for the period days 0—30 after either dose (108). None of the 
confirmed intussusception cases in either vaccine or placebo 
group had onset from days 0—14 after dose 1.
other Adverse Events
During the entire course of eight clinical studies, 68 (0.19%) 
deaths occurred among 36,755 RV1 recipients, and 50 (0.15%) 
deaths occurred among 34,454 placebo recipients (11). The 
most commonly reported cause of death after vaccination was 
pneumonia, which occurred in 19 (0.05%) RV1 recipients and 
10 (0.03%) placebo recipients (RR: 1.7; CI = 0.8-4.2).
Infants were monitored for SAEs that occurred in the 31-day 
period after vaccination in eight clinical studies (11). Severe dis­
ease from one or more SAE occurred in 627 (1.7%) o f36,755 
RV1 recipients compared with 659 (1.9%) of 34,454 placebo 
recipients (RR: 0.9; CI = 0.8-1.0). Diarrhea (RV1: 0.02%; 
placebo: 0.07%), dehydration (RV1: 0.02%; placebo: 0.06%), 
and gastroenteritis (RV1: 0.2%; placebo: 0.3%) occurred at a 
statistically higher (CI for relative risk excluded 1.0) incidence 
among placebo recipients compared with RV1 recipients. SAEs 
were coded with Medical Dictionary for Regulatory Activities 
(MedDRA) terms on the basis of information collected by 
study investigators from parental reports or medical records. 
Rates of SAEs were similar or the same between RV1 and pla­
cebo recipients for SAEs coded with the preferred MedDRA 
term “pneumonia” (RV1: 0.3%; placebo: 0.4%) and “convul­
sions” (RV1: 0.02%; placebo: 0.02%) (108).
In the Latin American trial, no notable differences were 
observed in the vaccinated versus placebo groups in rates of 
nonfatal pneumonia events and pneumonia hospitalizations 
(108). However, an increase was observed in pneumonia deaths 
(using combined pneumonia-related preferred terms) during 
the period between dose 1 and visit 3 [visit 3 took place 30-90 
days after dose 2]; 16 (0.05%) such deaths occurred among 
RV1 recipients, and six (0.02%) occurred among placebo 
recipients (risk difference: 3.2 per 10,000 infants; exact p = 
0.035) (108). In the European trial, no deaths were reported 
(108); rates of SAEs with the preferred term “pneumonia” 
reported from dose 1 to the end of the second rotavirus season
were significantly greater among RV1 recipients than among 
placebo recipients (0.9% and 0.3%, respectively) (risk differ­
ence: 61 per 10,000 infants; p = 0.03). In the RV1 group, 71% 
of the pneumonia SAEs occurred >153 days from the last dose 
of RV1 (111) (GSK, unpublished data, 2008). In all the other 
clinical trials in the BLA, and in the core integrated safety 
summary, statistically significant differences were not noted 
in the vaccine versus placebo groups for pneumonia or other 
pneumonia-related SAEs within the 31-day postvaccination 
period or for the full study period (111) (GSK, unpublished 
data, 2008). Excluding the Latin American safety and effi­
cacy trial, for all other BLA trials combined, no statistically 
significant differences were noted among the vaccine versus 
placebo groups in pneumonia-related deaths during the full 
study period. The significance of these pneumonia-related 
findings is unclear. Additional data are expected from studies 
nearing completion in Asia and Africa (Leonard Friedland, 
GSK, personal correspondence, June 2008).
In the Latin American trial, statistically significantly more 
events coded with the preferred term “convulsions” were 
reported from dose 1 to visit 3 in RV1 recipients (16 [0.05%]) 
compared with placebo recipients (6 [0.02%]; p = 0.03) (108). 
W hen convulsion-related preferred terms were combined, 
no statistically significant difference in these events occurred 
in RV1 recipients compared with placebo recipients in three 
periods that were analyzed: from dose 1 to visit 3 (RV1: 20 
[0.06%]; placebo: 12 [0.04%]), within 31 days after any dose 
(RV1: seven [0.02%]; placebo: nine [0.03%]), and 43 days 
after any dose (RV1: 12 [0.04%]; placebo: nine [0.03%]). 
In the European trial, no statistically significant difference 
was observed between convulsion-related SAEs in the RV1 
group compared with the placebo group within 31 or 43 days 
after any dose (one event in each group; 0.04% and 0.07%, 
respectively) (108).
In seven clinical studies, detailed safety information for 
solicited adverse events was collected by parents and guard­
ians for the day o f vaccination and the next 7 days. Adverse 
events among RV1 recipients and placebo recipients occurred 
at similar rates, with the exception of Grade 3 (i.e., those that 
prevented normal everyday activities) cough or runny nose, 
which was slightly but statistically significantly higher in the 
RV1 group (108) (Table 6). During the 31-day period after 
vaccination, the following unsolicited adverse events occurred 
at a statistically higher incidence among RV1 recipients com­
pared with placebo recipients: irritability (11.4% in RV1 group 
compared with 8.7% in the placebo group) and flatulence 
(2.2% in RV1 group compared with 1.3% in the placebo 
group) (11). No significant differences in Grade 3 irritability 
and flatulence were observed between the vaccine recipients 
and placebo recipients (108).
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TABLE 6. Percentage of in fants w ith so lic ited adverse events 
(any in tensity and Grade 3*) w ith in 8 days fo llow ing any dose 















Fever§ 39.8 0.9 48.8 1.1Fussiness/irritability 62.2 6.3 61.6 8.1
Loss of appetite 34.8 1.0 35.2 1.1Vomiting 17.6 3.4 15.8 2.7
Diarrhea 6.8 1.2 5.7 1.5Cough/runny nose^ 44.2 3.6** 47.2 3.2
SOURCE: Food and Drug Administration. Rotarix clinical review. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2008. Available at http://www.fda.gov/cber/products/rotarix/ rotarix031008rev.pdf.* Those that prevented normal everyday activities. t Percentages are per subject. Coadministration of routine infant vaccines allowed in studies that provided these data. Parents/guardians were asked to monitor for these events and record on a diary card.§ Fever, any intensity defined as temperature of >100.4°F (>38.0°C) rectally or >99.5°F (>37.5°C) orally/axillary. Grade 3 fever is defined as tempera­ture of >103.1°F (>39.5°C) rectally or >102.2°F (>39.0°C) orally/axillary.H This event was solicited among 2,584 RV1 recipients and 1,899 placebo recipients.** Statistically significantly higher (95% confidence interval for relative risk excluded 1.0) in RV1 group compared with placebo group.
In the placebo-controlled trials (including some that were not 
1:1 randomized), Kawasaki disease was reported in 17 (0.03%) 
RV1 recipients and nine (0.02%) placebo recipients (RR: 1.7; 
CI = 0.7-4.4); one case occurred within 30 days after study 
dose in RV1 recipients and one in the placebo recipients (RR: 
1.0; CI = 0.01-78.4) (11). Among RV1 recipients, the time of 
onset after study dose varied (range: 3 days—19 months).
Preterm Infants
A limited number of preterm infants (reported gestational 
age of <36 weeks) who received RV1 were followed for serious 
adverse events up to 30-90 days after dose 2. Serious adverse 
events were observed in seven (5.2%) of 134 preterm RV1 
recipients compared with six (5 .0 %) of 120 preterm placebo 
recipients (11). No deaths or cases of intussusception were 
reported among these infants. Additional data are expected 
in the near future.
Shedding and Transmission of 
Vaccine Virus
Rotavirus antigen shedding in stools postvaccination was 
evaluated in all or a subset of infants from seven phase II or III 
studies in various countries (RV1 administered at 106.5—106.8 
C C ID 50 per dose, with 26-152 infants evaluated per study) 
(108). After dose 1, rotavirus antigen shedding was detected 
by ELISA in 50.0% -80.0%  (depending on study) of infants
at approximately day 7, 19.2% -64.1%  at approximately 
day 15, 0-24.3%  at approximately day 30, and 0 - 2 .6 % at 
approximately day 60. After dose 2, rotavirus antigen shedding 
was detected in 4.2% -18.4%  (depending on study) of infants 
at approximately day 7 , 0-16.2%  at approximately day 15, 
0 - 1 .2 % at approximately day 30, and 0 at approximately day 
45 (day 45 was assessed in only one study).
Shedding of live rotavirus was assessed in two BLA studies 
in which RV1 was administered at 106.5 C C ID 50 per dose 
(108). In both studies, stool samples that were collected from 
a subset of infants at approximately day 7  after dose 1 were 
tested by ELISA. Stools that were rotavirus-antigen positive 
were tested subsequently for live virus by focus forming unit 
assay if enough sample was available. Live virus was detected 
in six (46.2%) o f 13 and 15 (45.5%) of 33 rotavirus-antigen 
positive stools, for an estimated 26% of vaccinated infants 
shedding live virus at approximately day 7  after dose 1 . The 
potential for transmission of vaccine virus to other persons 
was not assessed.
Cost-Effectiveness of Rotavirus 
Vaccination
In a 2006 analysis that considered rotavirus disease burden, 
vaccine efficacy, vaccine coverage rates, and health costs, 
investigators estimated that a national rotavirus vaccination 
program in which 3 doses of RV5 were administered at ages
2 , 4, and 6 months would result in 255,000 fewer physician 
visits, 137,000 fewer ED visits, 44,000 fewer hospitalizations, 
and 13 fewer deaths among children in one U.S. birth cohort 
followed to age 5 years (5). From the health-care perspective 
(i.e., evaluating medical costs only), the vaccination program 
was estimated to be cost-saving if the total cost per child 
(including administration costs) was less than $66  (in 2004 
dollars) for a complete series and would incur a net cost at 
$143 per child. From the societal perspective (i.e., evaluating 
medical and nonmedical costs), vaccination was likely to be 
cost-saving at a total cost per child of less than $156 and would 
be a net cost to society if total cost o f vaccination was more 
than $238 per child. At the manufacturer’s price of $62.50 (in 
2006 dollars) per dose, a rotavirus vaccination program with 
RV5 would cost an estimated $197,190 per life-year saved 
and $138 per case averted from the societal perspective. This 
analysis was repeated in 2008 for RV1 administered at ages
2 and 4 months (112). A national program with either the
3-dose RV5 series or the 2 -dose RV1 series will have similar 
cost-effectiveness estimates. Assuming a total cost o f $208 per 
child for RV1 and $218 per child for RV5 (in 2006 dollars; 
one extra $10  administration cost for RV5), RV1 was slightly 
more cost-effective than RV5 (e.g., from a societal perspective,
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median estimates of $94 compared with $139 per case averted 
and $128,400 compared with $198,546 per life-year saved, 
respectively). However, because of uncertainty in cost per dose, 
administration, and shipping for each product and of the field 
vaccine effectiveness of a product’s full or partial series, these 
differences in median estimates between the vaccines might 
not translate into a true difference for a program.
Rationale for Rotavirus Vaccination 
and Development of Updated 
Recommendations
The rationale for adopting vaccination of infants as the 
primary public health measure for prevention of rotavirus 
disease, especially severe rotavirus disease, in the United States 
is threefold. First, rates of rotavirus illness among children in 
industrialized and less developed countries were similar, indi­
cating that clean water supplies and good hygiene have little 
effect on virus transmission; therefore, further improvements in 
hygiene in the United States were unlikely to have a substantial 
impact on disease prevention (36,75,113—116). Second, in the 
United States, a high level of rotavirus morbidity continued 
in the prevaccine era despite available therapies. For example, 
the rate of hospitalizations for gastroenteritis in young children 
declined only modestly during 1979-1995 (8,117) despite 
the widespread availability o f oral rehydration solutions in 
the treatment o f dehydrating gastroenteritis (118,119). Third, 
studies of natural rotavirus infection indicated that initial infec­
tion protects against subsequent severe gastroenteritis, although 
subsequent asymptomatic infections and mild disease still 
might occur (75,76,120). Therefore, vaccination early in life, 
which mimics a child’s first natural infection, will not prevent 
all subsequent disease but should prevent the majority of cases 
of severe rotavirus disease and their sequelae (e.g., dehydration, 
physician visits, hospitalizations, and deaths).
In drafting and updating rotavirus vaccine recommenda­
tions for consideration by ACIP, the rotavirus vaccine work 
group acknowledged that differences existed in the design of 
the vaccine trials and studies and that these differences and the 
lack of a head-to-head trial between the two licensed vaccines 
limited direct comparisons o f some study results. One aspect 
that differed in the trials was the maximum ages for doses of 
vaccine. The maximum age for dose 1 in the trial protocols 
differed by approximately 3 weeks (Table 1). In addition, 
because the RV1 series has only 2 doses of vaccine whereas the 
RV5 series has 3 doses, the maximum age for the last dose for 
the RV1 trials was younger than that for the RV5 trial. W hen 
developing the recommendations for the maximum ages for 
doses, the workgroup considered the vaccines’ safety and effi­
cacy data and also the effect that having the same or different
maximum ages for the products would have on the ability of 
practitioners to follow the recommendations. After reviewing 
the options, the workgroup considered that harmonization of 
the maximum ages for doses of the two vaccines, as presented 
in the recommendations, would be unlikely to affect the safety 
and efficacy o f the vaccines and would be programmatically 
advantageous.
Changes to Recommendations from 
the 2006 ACIP Statement
• ACIP provides recommendations for use of a second rota­
virus vaccine, RV1, to be administered in a 2-dose series 
at ages 2 and 4 months.
• The maximum age for dose 1 o f rotavirus vaccine* is 
14 weeks and 6 days (previous recommendation: 12 
weeks).
• The maximum age for the last dose of rotavirus vaccine is 8 
months and 0 days (previous recommendation: 32 weeks).
• The minimum interval between doses of rotavirus vaccine 
is 4 weeks; no maximum interval is set (previous recom­
mendation: interval of 4-10  weeks between doses).
• Considerations that support rotavirus vaccination of HIV- 
exposed or infected infants are described below.
• Rotavirus vaccine may be administered at any time before, 
concurrent with, or after administration of any blood 
product, including antibody-containing products, fol­
lowing the routinely recommended schedule for rotavirus 
vaccine (previous recommendation: defer vaccination for 
42 days after receipt o f an antibody-containing product, 
if possible).
Recom m endations fo r the Use  
of R otavirus Vaccine  
Routine Administration
ACIP recommends routine vaccination of U.S. infants with 
rotavirus vaccine (Table 7). Two different rotavirus vaccine 
products are licensed for use in infants in the United States, 
RV 5 and RV1. The products differ in composition and schedule 
of administration. Safety and efficacy were demonstrated for 
both vaccines in prelicensure clinical trials. Efficacy studies 
demonstrated that rotavirus vaccine was 85% -98%  protec­
tive against severe rotavirus disease and 74% -87%  protective 
against rotavirus disease of any severity through approximately 
the first rotavirus season (93,109,110). ACIP does not express 
a preference for either RV5 or RV1.
* In these recommendations, the term “rotavirus vaccine” is used to refer to both
RV5 and RV1.
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Routine vaccination with RotaTeq® at ages 2, 4, and 6 mos or with Rotarix® at ages 2 and 4 mos I AAdminister to breastfed infants I A
Coadminister with DTaP,§ H b  vaccine, IPV,** hepatitis B vaccine, and pneumococcal conjugate vaccine I AAdminister to infants with mild illness, including gastroenteritis I B
ContraindicationsSevere allergic reaction to a vaccine component or a previous vaccine dose III B
PrecautionsAltered immunocompetence III C
Moderate or severe acute illness, including gastroenteritis III CChronic gastrointestinal disease III C
History of intussusception III CInfants with spina bifida or bladder exstrophy III C
Special situationsPreterm infants (<37 weeks’ gestation) I B
Infants living in households with immunocompromised persons III CInfants living in households with pregnant women III CRegurgitation of vaccine III C
Infants hospitalized after vaccination III CInfants who have received antibody-containing blood products III C
* I = evidence from randomized controlled studies; II = evidence from other epidemiologic studies; and III = opinion of authorities. t A = good evidence to support recommendation; B = fair evidence to support recommendation; and C = insufficient evidence.§ Diphtheria and tetanus toxoids and acellular pertussis vaccine.H Haemophilus influenzae type b conjugate.** Inactivated poliovirus vaccine.
RV5 is to be administered orally in a 3-dose series, with 
doses administered at ages 2, 4, and 6 months. RV1 is to be 
administered orally in a 2-dose series, with doses administered 
at ages 2 and 4 months (Table 8). The minimum age for dose 
1 of rotavirus vaccine is 6 weeks; the maximum age for dose 1 
is 14 weeks and 6 days. Vaccination should not be initiated for 
infants aged 15 weeks and 0 days or older because of insufficient 
data on safety o f dose 1 of rotavirus vaccine in older infants. 
The minimum interval between doses of rotavirus vaccine 
is 4 weeks; no maximum interval is set. All doses should be 
administered by age 8 months and 0 days.
For infants to whom dose 1 of rotavirus vaccine is admin­
istered inadvertently at age 15 weeks and 0 days or older, the 
rest o f the rotavirus vaccination series should be completed 
according to the schedule and by age 8 months and 0 days 
because timing o f dose 1 should not affect the safety and effi­
cacy of any subsequent dose(s). Infants who have had rotavirus 
gastroenteritis before receiving the full series of rotavirus vac­
cination should still start or complete the schedule according 
to the age and interval recommendations because the initial 
rotavirus infection might provide only partial protection 
against subsequent rotavirus disease.
No restrictions are placed on the infant’s feeding before or 
after receipt of rotavirus vaccine. Breastfed infants should be 
vaccinated according to the same schedule as nonbreastfed
infants. The efficacy o f the rotavirus vaccine series is similar 
among breastfed and nonbreastfed infants. As with all other 
vaccines, rotavirus vaccine can be administered to infants with 
minor acute illness (e.g., mild gastroenteritis or mild upper- 
respiratory tract infection, with or without feverj.
Simultaneous Administration
Rotavirus vaccine can be administered together with DTaP 
vaccine, Hib vaccine, IPV, hepatitis B vaccine, and pneumococ­
cal conjugate vaccine. Available evidence suggests that rotavirus 
vaccine does not interfere with the immune response to these 
vaccines (for each rotavirus vaccine, see Immunogenicity). The 
infant’s immune response to influenza vaccine administered 
at the same time as rotavirus vaccine has not been studied. 
However, ACIP has recommended previously that an inac­
tivated vaccine (e.g., inactivated influenza vaccine) may be 
administered either simultaneously or at any time before or 
after a different inactivated vaccine or live vaccine (e.g., rota­
virus vaccine) (121).
Interchangeability of Rotavirus 
Vaccines
ACIP recommends that the rotavirus vaccine series be com­
pleted with the same product whenever possible. However, 
vaccination should not be deferred because the product used
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TABLE 8. Schedule fo r adm inistration of rotavirus vaccines
Vaccine
Characteristic RV5* RV1 +
No. doses in series 3 2
Recommended ages for doses 2, 4, and 6 mos 2 and 4 mos
Minimum age for first dose 6 wks
Maximum age for first dose 14 wks and 6 days
Minimum interval between doses 4 wks
Maximum age for last dose 8 mos and 0 days
* RotaTeq®.t Rotarix®.
for a previous dose(s) is not available or is unknown. In these 
situations, the provider should continue or complete the series 
with the product available. If any dose in the series was RV5 
or the vaccine product is unknown for any dose in the series, a 
total of 3 doses of rotavirus vaccine should be administered. All 
doses should be administered by age 8 months and 0 days.
No studies address the interchangeability of the two rotavi­
rus vaccine products. However, no theoretic reason exists to 
expect that the risk for adverse events would be increased if 
the series included more than one product, compared with the 
risk for adverse events of a series containing only one product. 
Further, although it is possible that effectiveness o f a series that 
contained both products could be reduced compared with a 
complete series with one product, the effectiveness o f a series 
that contains both products is likely to be greater than an 
incomplete series with one product.
Contraindications
Rotavirus vaccine should not be administered to infants who 
have a history of a severe allergic reaction (e.g., anaphylaxis) 
after a previous dose of rotavirus vaccine or to a vaccine com­
ponent. Latex rubber is contained in the RV1 oral applicator, 
so infants with a severe (anaphylactic) allergy to latex should 
not receive RV1. The RV5 dosing tube is latex-free.
Precautions
Altered Immunocompetence
Practitioners should consider the potential risks and benefits 
of administering rotavirus vaccine to infants with known or 
suspected altered immunocompetence (121); consultation with 
an immunologist or infectious diseases specialist is advised. 
Children and adults who are immunocompromised because of 
congenital immunodeficiency, hematopoetic transplantation, 
or solid organ transplantation sometimes experience severe 
or prolonged rotavirus gastroenteritis. However, no safety or
efficacy data are available for the administration of rotavirus 
vaccine to infants who are immunocompromised or potentially 
immunocompromised, including 1) infants with primary and 
acquired immunodeficiency states, cellular immunodeficien­
cies, and hypogammaglobulinemic and dysgammaglobulinemic 
states; 2) infants with blood dyscrasias, leukemia, lymphomas, 
or other malignant neoplasms affecting the bone marrow or 
lymphatic system; 3) infants on immunosuppressive therapy 
(including high-dose systemic corticosteroids); and 4) infants 
who are HIV-exposed or infected. However, two considerations 
support vaccination of HIV-exposed or infected infants: first, 
the HIV  diagnosis might not be established in infants born 
to HIV-infected mothers before the age of the first rotavirus 
vaccine dose (only 1.5%—3% of HIV-exposed infants in the 
United States will be determined to be HIV-infected); and sec­
ond, vaccine strains of rotavirus are considerably attenuated.
Acute Gastroenteritis
In usual circumstances, rotavirus vaccine should not be 
administered to infants with acute moderate or severe gastro­
enteritis until the condition improves. However, infants with 
mild acute gastroenteritis can be vaccinated, particularly if the 
delay in vaccination might be substantial and might make the 
infant ineligible to receive vaccine (e.g., aged >15 weeks and 
0 days before the vaccine series is started). Rotavirus vaccine 
has not been studied among infants with concurrent acute gas­
troenteritis. In these infants, the immunogenicity and efficacy 
o f rotavirus vaccine theoretically could be compromised. For 
example, in some instances, infants who received OPV during 
an episode of acute gastroenteritis had diminished poliovirus 
antibody responses (122).
Moderate or Severe Acute Illness
As with all other vaccines, the presence of a moderate or 
severe acute illness with or without fever is a precaution to 
administration of rotavirus vaccine. Infants with a moderate 
or severe acute illness should be vaccinated as soon as they 
have recovered from the acute phase of the illness. This pre­
caution avoids superimposing any potential adverse effects of 
the vaccine on the underlying illness or mistakenly attribut­
ing a manifestation of the underlying illness to the vaccine. 
Vaccination should not be delayed because of the presence of 
mild respiratory tract illness or other mild acute illness with 
or without fever.
Pre-existing Chronic Gastrointestinal 
Diseases
Infants with pre-existing gastrointestinal conditions (e.g., 
congenital malabsorption syndromes, Hirschsprung’s disease, 
or short-gut syndrome) who are not undergoing immuno­
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suppressive therapy should benefit from receiving rotavirus 
vaccine, and ACIP considers the benefits to outweigh the 
theoretic risks. However, no data are available on the safety 
and efficacy o f rotavirus vaccine for infants with preexisting 
chronic gastrointestinal conditions.
Previous History of Intussusception
Practitioners should consider the potential risks and benefits 
of administering rotavirus vaccine to infants with a previous 
history of intussusception. Available data do not indicate that 
RV5 or RV1 are associated with intussusception. A previously 
licensed rotavirus vaccine that is no longer available in the 
United States, RRV-TV, was associated with an increased risk 
for intussusception. Compared with infants who have never 
had intussusception, infants with a history o f intussusception 
are at higher risk for a repeat episode of intussusception. No 
data are available on the administration o f rotavirus vaccine 
to infants with a history of intussusception.
Infants with Spina Bifida or Bladder 
Exstrophy
Latex rubber is contained in the RV1 oral applicator whereas 
the RV5 dosing tube is latex-free. Therefore, some experts prefer 
that infants with spina bifida or bladder exstrophy, who are 
at high risk for acquiring latex allergy, receive RV5 instead of 
RV1 to minimize latex exposure in these children. However, 
if RV1 is the only rotavirus vaccine available, it should be 
administered, because the benefit of vaccination is considered 
to be greater than the risk for sensitization.
Special Situations
Preterm Infants (<37 W eeks' Gestation)
ACIP considers the benefits of rotavirus vaccination of 
preterm infants (those born at <37 weeks’ gestation) to out­
weigh the risks of adverse events. Data suggest that preterm 
infants are at increased risk for hospitalization from rotavirus 
or other viral pathogens associated with gastroenteritis during 
their first one to two years of life. In clinical trials, rotavirus 
vaccine appeared to be generally well tolerated in preterm 
infants, although a relatively small number of preterm infants 
have been evaluated (for each rotavirus vaccine, see Adverse 
Events After Immunization).
ACIP supports vaccination of preterm infants according to 
the same schedule and precautions as full-term infants and 
under the following conditions: the infant’s chronological age 
meets the age requirements for rotavirus vaccine (e.g., age 6 
weeks—14 weeks and 6 days for dose 1), the infant is clinically 
stable, and the vaccine is administered at the time of discharge 
from the neonatal intensive care unit [NICU] or nursery, or
after discharge from the N IC U  or nursery. Although the lower 
level o f maternal antibody to rotavirus in very preterm infants 
theoretically could increase the risk for adverse reactions from 
rotavirus vaccine, ACIP believes the benefits of vaccinating the 
infant when age-eligible, clinically stable, and no longer in the 
hospital outweigh the theoretic risks.
Vaccine strains o f rotavirus are shed in stools o f vacci­
nated infants (for each rotavirus vaccine, see Shedding and 
Transmission o f Vaccine Virus), so if an infant were to be 
vaccinated with rotavirus vaccine while still needing care in 
the N IC U  or nursery, at least a theoretic risk exists for vaccine 
virus being transmitted to infants in the same unit who are 
acutely ill (moderate or severe acute illness is a precaution for 
vaccination) and to preterm infants who are not age-eligible 
for vaccine. ACIP considers that, in usual circumstances, the 
risk from shedding outweighs the benefit of vaccinating the 
infant who is age-eligible for vaccine but who will remain in 
the N IC U  or nursery after vaccination.
Exposure of Immunocompromised Persons 
to Vaccinated Infants
Infants living in households with persons who have or are 
suspected of having an immunodeficiency disorder or impaired 
immune status can be vaccinated. Vaccine virus (attenu­
ated rotavirus) is shed in the stools o f infants after rotavirus 
vaccination. However, no data are available on the risk for 
transmission of vaccine virus to household contacts and the 
risk for any subsequent disease. Vaccine virus is shed more 
commonly and for longer periods after RV1 than after RV5 
(for each rotavirus vaccine, see Shedding and Transmission of 
Vaccine Virus). ACIP believes that the protection of the immu­
nocompromised household member afforded by vaccinating 
the infant in the household and preventing wild-type rotavirus 
disease outweighs the small risk for transmitting vaccine virus 
to the immunocompromised household member and any 
subsequent theoretic risk for vaccine virus-associated disease. 
Vaccine virus is shed during the first weeks after administra­
tion of rotavirus vaccine; handwashing after diaper changing 
is always recommended.
Exposure of Pregnant Women to Vaccinated 
Infants
Infants living in households with pregnant women should 
be vaccinated according to the same schedule as infants in 
households without pregnant women. Because the majority 
of women of childbearing age have preexisting immunity to 
rotavirus, the risk for infection and any subsequent theoretic 
risk for disease from potential exposure to the attenuated vac­
cine virus is considered to be very low.
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Regurgitation of Vaccine
The practitioner should not readminister a dose of rotavirus 
vaccine to an infant who regurgitates, spits out, or vomits 
during or after administration of vaccine. No data exist on 
the benefits or risks associated with readministering a dose. 
The infant should receive the remaining recommended doses 
of rotavirus vaccine following the routine schedule (with a
4-week minimum interval between doses).
Hospitalization After Vaccination
If a recently vaccinated infant is hospitalized for any rea­
son, no precautions other than standard precautions need 
to be taken to prevent spread of vaccine virus in the hospital 
setting.
Infants W ho Have Recently Received or Will 
Receive an Antibody-Containing Blood 
Product
Rotavirus vaccine may be administered at any time before, 
concurrent with, or after administration o f any blood prod­
uct, including antibody-containing products, following the 
routinely recommended schedule for rotavirus vaccine among 
infants who are eligible for vaccination. No data are available 
on the immune response to rotavirus vaccine in infants who 
have recently received a blood product. In theory, infants who 
have recently received an antibody-containing blood product 
might have a reduced immunologic response to a dose of oral 
rotavirus vaccine. However, 2 or 3 doses of vaccine are admin­
istered in the full rotavirus vaccine series, and no increased risk 
for adverse events is expected.
Reporting of Adverse Events
Any clinically significant or unexpected adverse event that 
occurs after administration of rotavirus vaccine should be 
reported to VAERS, even if a causal relation to vaccination 
is not certain. The National Childhood Vaccine Injury Act 
requires health-care providers to maintain permanent immu­
nization records and to report to VAERS occurrences of 
specific adverse events that follow selected vaccines, including 
rotavirus vaccine (available at http://vaers.hhs.gov/reportable. 
htm). VAERS reporting forms and information are available 
electronically at http://vaers.hhs.gov or by telephone, 1-800­
822-7967. Web-based reporting by providers is encouraged 
and is available at https://secure.vaers.org/VaersDataEntryinto. 
htm.
Enhanced Postlicensure Surveillance 
for Adverse Events
Monitoring for adverse events after introduction of rotavi­
rus vaccine into routine vaccination programs is important, 
particularly in light of the previous experience with RRV-TV 
and its association with intussusception. The monitoring after 
introduction of RV1 will be similar to that conducted for RV5 
and will include manufacturer-sponsored phase IV studies and 
enhanced review of adverse events reported to VAERS.
National Vaccine Injury 
Compensation Program
T he N ational Vaccine Injury C om pensation Program 
(VICP), established by the National C hildhood Vaccine 
Injury Act of 1986, is a no-fault system through which per­
sons thought to have suffered an injury or death as a result of 
administration o f a covered vaccine can seek compensation. 
Persons of all ages who receive a VICP-covered vaccine are 
eligible to file a claim.
The program relies on a vaccine injury table listing the 
vaccines covered by the program and the injuries, disabili­
ties, illnesses, and conditions (including death) for which 
compensation can be awarded. Claimants also can prevail for 
conditions not listed in the table if they can prove causation. 
For a claimant to be eligible for compensation, claims must be 
filed within a specific time period after the injury.
Rotavirus vaccine is covered by VICP under the general 
category of rotavirus vaccines in Category XI o f the Vaccine 
Injury Table (available at http://www.hrsa.gov/vaccinecompen- 
sation/table.htm). In this category, no condition is specified 
for compensation. Additional information about the program 
is available at http://www.hrsa.gov/vaccinecompensation or by 
telephone, 1-800-338-2382.
Areas for Study Related to Rotavirus 
Vaccination
Surveillance of Rotavirus Gastroenteritis
Rotavirus gastroenteritis is not a reportable disease in the 
United States, and testing for rotavirus infection is not always 
performed when a child seeks medical care for acute gastro­
enteritis. Rotavirus disease surveillance systems need to be 
adequately sensitive and specific to document the effective­
ness o f the vaccination program. Methods of surveillance for 
rotavirus disease at the national level include review of national 
hospital discharge databases for rotavirus-specific or rotavirus- 
compatible diagnoses, surveillance for rotavirus disease at three 
sites that participate in NVSN, and reports of rotavirus detec­
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tion from a sentinel system of laboratories (6,7,14). At the state 
and local levels, surveillance efforts at sentinel hospitals or by 
review of hospital discharge databases can be used to monitor 
the impact o f the vaccine program. Special studies (e.g., case- 
control studies and retrospective cohort studies) will be used 
to measure the effectiveness of rotavirus vaccine under routine 
use in the United States.
Detection of Unusual Strains of Rotavirus
C D C has established a national strain surveillance system 
of sentinel laboratories to monitor circulating rotavirus strains 
before and after the introduction of rotavirus vaccine (64—66). 
This system is designed to detect new or unusual strains caus­
ing gastroenteritis that might not be prevented effectively by 
vaccination, which might affect the success of the vaccination 
program.
Research
Additional studies would be valuable to evaluate the safety 
and efficacy o f rotavirus vaccine administered to infants who 
are born preterm, have immune deficiencies, live in households 
with immunocompromised persons, have chronic gastrointes­
tinal disease, or start the series late. Postlicensure studies also 
could determine the relative effectiveness of rotavirus vaccine 
when less than the full series is administered and evaluate pos­
sible secondary transmission of vaccine virus.
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